ME00937B - Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera - Google Patents

Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera

Info

Publication number
ME00937B
ME00937B MEP-2009-304A MEP30409A ME00937B ME 00937 B ME00937 B ME 00937B ME P30409 A MEP30409 A ME P30409A ME 00937 B ME00937 B ME 00937B
Authority
ME
Montenegro
Prior art keywords
pi3k
cancer
alpha
treatment
combination therapies
Prior art date
Application number
MEP-2009-304A
Other languages
English (en)
French (fr)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ME00937B publication Critical patent/ME00937B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
MEP-2009-304A 2007-04-11 2008-04-08 Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera ME00937B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11
PCT/US2008/004570 WO2008127594A2 (en) 2007-04-11 2008-04-08 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
ME00937B true ME00937B (me) 2012-06-20

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-304A ME00937B (me) 2007-04-11 2008-04-08 Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera

Country Status (34)

Country Link
US (1) US8481001B2 (me)
EP (1) EP2139483B9 (me)
JP (2) JP5726515B2 (me)
KR (1) KR101586774B1 (me)
CN (2) CN103202842A (me)
AU (1) AU2008239668B2 (me)
BR (1) BRPI0810208A2 (me)
CA (1) CA2684056A1 (me)
CO (1) CO6140024A2 (me)
CR (1) CR11099A (me)
CY (1) CY1114608T1 (me)
DK (1) DK2139483T3 (me)
EA (1) EA019064B1 (me)
EC (1) ECSP099723A (me)
ES (1) ES2438998T3 (me)
GT (1) GT200900263A (me)
HK (1) HK1140141A1 (me)
HR (1) HRP20131081T1 (me)
IL (1) IL201211A (me)
MA (1) MA31335B1 (me)
ME (1) ME00937B (me)
MX (1) MX2009010929A (me)
MY (1) MY150797A (me)
NI (1) NI200900184A (me)
NZ (1) NZ580009A (me)
PL (1) PL2139483T3 (me)
PT (1) PT2139483E (me)
RS (1) RS53020B (me)
SI (1) SI2139483T1 (me)
SV (1) SV2009003390A (me)
TN (1) TN2009000399A1 (me)
UA (1) UA98141C2 (me)
WO (1) WO2008127594A2 (me)
ZA (1) ZA200906765B (me)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
JP5270353B2 (ja) * 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
UA100979C2 (ru) * 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
JP5687903B2 (ja) * 2008-11-10 2015-03-25 協和発酵キリン株式会社 キヌレニン産生抑制剤
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
TW201139436A (en) 2010-02-09 2011-11-16 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
WO2012006552A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
DE102010048800A1 (de) * 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
CN103270027A (zh) 2010-10-20 2013-08-28 默克雪兰诺日内瓦有限公司 制备取代的n-(3-氨基-喹喔啉-2-基)-磺酰胺和它们的中间体n-(3-氯-喹喔啉-2-基)-磺酰胺的方法
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
EP2755654A1 (en) * 2011-09-14 2014-07-23 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
CN104024257A (zh) * 2011-10-04 2014-09-03 吉利德卡利斯托加有限责任公司 Pi3k的新的喹喔啉抑制剂
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
AU2012328979B2 (en) * 2011-10-28 2016-04-21 Novartis Ag Method of treating gastrointestinal stromal tumors
CN107375289A (zh) 2011-11-01 2017-11-24 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
WO2013101964A1 (en) * 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
EP2860181B1 (en) 2012-04-10 2019-02-13 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition and uses thereof
US9487526B2 (en) 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
US9745321B2 (en) 2013-09-30 2017-08-29 Shanghai Yingli Pharmaceutical Co., Ltd Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
WO2015055071A1 (zh) 2013-10-16 2015-04-23 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
WO2015123505A1 (en) 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
WO2007023186A1 (en) * 2005-08-26 2007-03-01 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
JP5270353B2 (ja) * 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
US8614215B2 (en) * 2007-02-22 2013-12-24 Merck Serono Sa Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks)
UA100979C2 (ru) * 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
WO2008127594A3 (en) 2009-04-30
CY1114608T1 (el) 2016-10-05
JP5726515B2 (ja) 2015-06-03
EA019064B1 (ru) 2013-12-30
CR11099A (es) 2010-01-19
ECSP099723A (es) 2010-03-31
MY150797A (en) 2014-02-28
EP2139483B9 (en) 2014-05-21
CN101959516B (zh) 2013-05-08
TN2009000399A1 (fr) 2010-12-31
GT200900263A (es) 2014-01-15
MA31335B1 (fr) 2010-04-01
EP2139483B1 (en) 2013-09-18
JP2010523669A (ja) 2010-07-15
CN103202842A (zh) 2013-07-17
PL2139483T3 (pl) 2014-02-28
CA2684056A1 (en) 2008-10-23
HRP20131081T1 (hr) 2013-12-20
KR101586774B1 (ko) 2016-01-19
UA98141C2 (ru) 2012-04-25
SI2139483T1 (sl) 2013-11-29
PT2139483E (pt) 2013-12-27
EA200970935A1 (ru) 2010-04-30
AU2008239668B2 (en) 2013-11-07
BRPI0810208A2 (pt) 2014-10-21
CO6140024A2 (es) 2010-03-19
ZA200906765B (en) 2010-05-26
IL201211A (en) 2015-09-24
US20110123434A1 (en) 2011-05-26
SV2009003390A (es) 2010-05-21
EP2139483A2 (en) 2010-01-06
KR20100019436A (ko) 2010-02-18
ES2438998T3 (es) 2014-01-21
AU2008239668A1 (en) 2008-10-23
HK1140141A1 (en) 2010-10-08
RS53020B (en) 2014-04-30
WO2008127594A2 (en) 2008-10-23
NZ580009A (en) 2012-06-29
NI200900184A (es) 2011-09-08
MX2009010929A (es) 2010-01-20
US8481001B2 (en) 2013-07-09
DK2139483T3 (da) 2014-01-13
IL201211A0 (en) 2010-05-31
JP2014074031A (ja) 2014-04-24
CN101959516A (zh) 2011-01-26

Similar Documents

Publication Publication Date Title
ZA200906765B (en) Combination therapies comprising quinoxaline inhibitors of P13K-Alpha for use in the treatment of cancer
IL219253A (en) Benzodiazepine inhibiting bromodomain for cancer treatment
PT2601962T (pt) Regime de dosagem de lag-3 para utilização no tratamento de cancro
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
ZA200908477B (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
EP2173740A4 (en) INHIBITORS OF HEMOXYGENASE AND THEIR USE IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
PL2040753T3 (pl) Inhibitory progastryny w leczeniu raka okrężnicy
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
HK1256479A1 (zh) 在治療癌症中grn163l用作端粒酶抑制劑
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
HK1151971A1 (en) Compounds for use in the treatment of cancer
PL2320900T3 (pl) Opioidy do zastosowania w leczeniu opornych pacjentów onkologicznych
EP1917041A4 (en) USE OF FRUCTOSE-BASED THERAPIES FOR CANCER TREATMENT
IL226363A0 (en) Compounds and methods for treating cancer
HK1209754A1 (en) Compounds and methods for the treatment of cancer
GB0604794D0 (en) Spisulosine compounds for use in cancer therapy
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0604114D0 (en) Combinations for the treatment of cancer